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Abstract: In efforts to enhance the activity of liposomal drugs against solid tumors, three novel lipids
that carry imidazole-based headgroups of incremental basicity were prepared and incorporated into
the membrane of PEGylated liposomes containing doxorubicin (DOX) to render pH-sensitive convertible liposomes (ICL). The imidazole lipids were designed to protonate and cluster with negatively
charged phosphatidylethanolamine-polyethylene glycol when pH drops from 7.4 to 6.0, thereby
triggering ICL in acidic tumor interstitium. Upon the drop of pH, ICL gained more positive surface
charges, displayed lipid phase separation in TEM and DSC, and aggregated with cell membranemimetic model liposomes. The drop of pH also enhanced DOX release from ICL consisting of one
of the imidazole lipids, sn-2-((2,3-dihexadecyloxypropyl)thio)-5-methyl-1H-imidazole. ICL demonstrated superior activities against monolayer cells and several 3D MCS than the analogous PEGylated,
pH-insensitive liposomes containing DOX, which serves as a control and clinical benchmark. The
presence of cholesterol in ICL enhanced their colloidal stability but diminished their pH-sensitivity.
ICL with the most basic imidazole lipid showed the highest activity in monolayer Hela cells; ICL
with the imidazole lipid of medium basicity showed the highest anticancer activity in 3D MCS. ICL
that balances the needs of tissue penetration, cell-binding, and drug release would yield optimal
activity against solid tumors.
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1. Introduction
The past two decades have seen a surge in the medical use of nanotechnology.
Tens of nanomedicines, mostly liposomes, have been approved by Food and Drug
Administration (FDA) or European Medicines Agency (EMA) to treat or diagnose many
serious diseases, especially various types of cancer [1–4]. Liposomal formulations of
doxorubicin (DOX) [4–6] represent an important group of nanomedicines, which are
indicated for a wide range of cancers. Many studies have demonstrated that, compared
with free DOX, DOX-loaded nanomedicines offer substantially lower cardiotoxicity and
higher efficacy, both owing to their preferred accumulation at tumor sites [7,8].
One abnormal feature in many solid tumors is a fenestrated vasculature [9], which
allows nano-formulations of anticancer drugs to permeate selectively from the blood
circulation to the tumor interstitium. The nano-formulations can then accumulate in solid
tumors due to their lack of lymphatic drainage, a phenomenon known as the enhanced
permeability and retention (EPR) effect. Many long-circulating nano-formulations have
been developed to take advantage of the EPR effect, including PEGylated liposomes,
hydrophilic polymers, and solid lipid nanoparticles [10,11]. However, the fenestrated
vasculature distributes mainly in the peripheral of solid tumors, which could limit the
distribution of nano-drug formulations to the tumor core, and hence limit their ability to
eradicate the entire tumor cell population [12].
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Another abnormality of tumor tissue is its acidic microenvironment. Whereas normal cells in healthy tissues have an intracellular pH (pHi ) of 7.2 and a slightly higher
extracellular pH (pHe ) of 7.4, cancer cells in tumors are characterized by a pHi of 7.2
but a significantly lower pHe of 6.2–7.0 [13,14]. The lower pHe in the tumor interstitium
results from the accumulation of lactate, an acidic by-product of the elevated anaerobic
metabolism by the cancer cells in the hypoxic tumor microenvironment [15]. In response,
many pH-sensitive drug delivery systems have been developed, including pH-sensitive
liposomes, antibody-drug conjugates with acid-labile linkers, and pH-sensitive polymeric
nanoparticles [16–18]. A number of pH-sensitive drug delivery systems have shown enhanced anticancer activity compared to their pH-insensitive counterparts in preclinical
research [19,20]. However, pH-sensitive nano-drug delivery systems have not yet been
approved to treat cancer patients.
Imidazole represents an important pH-sensitive functional group in pharmaceutical sciences. Imidazoles carry pKa values around 5.0–6.5 and thus can protonate
to assume a positive charge in response to weakly acidic pH in pathophysiological
settings [21]. The incorporation of imidazole-based lipids into nano-formulations has
enhanced their intracellular delivery of proteins and nucleic acids [22,23]. However,
very few studies [24] have been reported on imidazole-based nano-formulations for
anticancer drug delivery.
Herein, we report a novel type of imidazole lipids and their pH-sensitive liposomes. Our goal is to develop imidazole lipids that trigger the liposomes in cooperation
with phosphatidylethanolamine-polyethylene glycol conjugates (PE-PEG), which is a
key component to stabilize liposomes in blood circulation for anticancer drug delivery. At pH 7.4, the imidazole lipids are mostly uncharged, while at acidic pH, they
would protonate and cluster with negatively charged PE-PEG to induce lipid phase
conversions. Such liposomes are thus called imidazole-based convertible liposomes
(ICL) (Figure 1). ICL was loaded with the anticancer drug doxorubicin (DOX) and
subjected to physicochemical and morphological characterizations. The pH-sensitivity
of ICL was assessed by Differential Scanning Calorimetry (DSC), change of ζ-potential,
interaction with negatively charged model lipid membranes, and pH-dependent drug
release. The anticancer activities of ICL were assessed against both 2D monolayer
cancer cells and 3D multicellular tumor spheroids (MCS), which mimic more features
of solid tumors than 2D cell cultures, including the acidic microenvironment, the
dense ECM, and the hypoxic core [9,25]. PEGylated liposomes containing DOX but not
the pH-sensitive, imidazole-based lipids were also studied, both as a pH-insensitive
control and as a benchmark of clinically used liposomal formulations. The effects of
cholesterol on the physicochemical properties, pH-sensitivity and anticancer activities
of ICL were also investigated. We report the physicochemical properties and the superior anticancer activities of ICL in both monolayer cancer cells and MCS of multiple
cancer cell lines in correlation to their pH-sensitivity.

Pharmaceuticals 2022, 15, 306

3 of 23

als 2022, 15, x FOR PEER REVIEW

3 of 23

Figure 1. Imidazole-based convertible liposome (ICL). (A) Chemical structures of lipids that constiFigure 1. Imidazole-based convertible liposome (ICL). (A) Chemical structures of lipids that constitute
tute ICL. (B) Schematic of ICL turning from stealth liposomes into cationic liposomes in acidic tumor
ICL. (B) Schematic of ICL turning from stealth liposomes into cationic liposomes in acidic tumor
interstitium. P-, negatively charged phosphate group in DPPE-PEG; N/N+, basic amine in imidazinterstitium. P−, negatively charged phosphate group in DPPE-PEG; N/N+, basic amine in imidazoleole-based lipids.
based lipids.
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novel lipids
(Figure 2),
namely sn-2-((2,3-dihexadecyloxypropyl)thio)-1H-imida
Three novel lipids
2), namely
sn-2-((2,3-dihexadecyloxypropyl)thio)-1H-im-zole (DHI), sn-2-((2,3-dihexadecyloxypropyl)thio)-5-methyl-1H-imidazole (DHMI), and
idazole (DHI), sn-2-((2,3-dihexadecyloxypropyl)thio)-5-methyl-1H-imidazole (DHMI),
and sn-2-((2,3-dihexadecyloxypropyl)thio)-4,5-dimethyl-1H-imidazole (DHDMI) were
designed as a critical component of ICL. Each of the lipids contains two saturated hexadecyl (C16) hydrocarbon chains as the tail and an imidazole-based headgroup. In a typical
anticancer liposome formulation, the C16 chains would make the novel lipids more com-
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Figure 3. Synthesis of imidazole-based, pH-sensitive lipids.
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choline headgroup and a tail of two long (C18), saturated hydrocarbon chains; DPPE-PEG
is a conjugate of PEG2000 and phosphoethanolamine with a negative charge from the
phosphate, and a tail of two long (C16) saturated hydrocarbon chains. At pH 7.4, the
lipids would assemble into a stable lipid membrane of ICL that is evenly coated by PEG
as in sterically hindered, long-circulating liposomes [6,8]. In response to lowered pH, the
imidazole-based lipids in ICL would be protonated to assume positive charges and cluster
with negatively charged DPPE-PEG (2000) by electrostatic interactions (Figure 1B). Such
pH-triggered clustering of lipids would expose part of the ICL surface that is no longer
sterically hindered by PEG, which would then enhance the interaction between ICL and
cancer cells in the acidic tumor interstitium [26]. The ICL-cancer cell interactions could also
be enhanced by the excess positive charges on the ICL surface [26]. Furthermore, the pHtriggered lipid clustering could enhance the release of the liposome contents through the
edges between the DPPE-PEG-rich and DPPE-PEG-poor regions of the liposome membrane
based on our prior studies on liposomes consisting of pH-sensitive conformational switches
of lipid tails [27,28]. As a common lipid component to improve the stability of liposomes,
cholesterol [29,30] was included in some of the formulations under investigation. Cholesterol was incorporated at 25 mol%, a level that tends to improve the liposome stability both
on the shelf and in blood circulation. Analogous liposomes without imidazole-based lipids
were also prepared and characterized as pH-insensitive controls.
2.3. Physicochemical Characteristics of ICL
After lipidic film hydration, freeze-anneal-thawing and sequential extrusion through
400 nm, 200 nm and 100 nm polycarbonate membranes, ICL consisting of 25 mol% DHI,
DHMI or DHMI were successfully prepared with mean hydrodynamic diameters smaller
than 130 nm (Table 1). The Polydispersity Index (PDI), a measure of the heterogeneity of
the size of particles in a mixture, was lower than 0.3 for all the liposome formulations. The
liposomes with 25 mol% cholesterol showed generally smaller PDI than the cholesterol-free
formulations. After being loaded with DOX, all the formulations were characterized with
larger sizes and PDI. Nevertheless, the sizes of all the DOX-loaded formulations were
below or around 200 nm in diameter. The DOX-loaded ICL with 25% cholesterol showed
smaller sizes and PDI than the DOX-loaded ICL without cholesterol. The encapsulation
efficiency (EE) of all the formulations was 50% or higher, and ICL with cholesterol were
characterized with considerably higher EE than cholesterol-free ICL.
Table 1. Physicochemical characteristics of DOX-free and DOX-loaded ICL in comparison with
pH-insensitive stealth liposomes.
Before DOX-Loading
Lipid Compositions
DHI/DSPC/
DPPE-PEG
DHMI/DSPC/
DPPE-PEG
DHDMI/DSPC/
DPPE-PEG
DSPC/DPPE-PEG
DHI/DSPC/DPPEPEG/Chol
DHMI/DSPC/DPPEPEG/Chol
DHDMI/DSPC/DPPEPEG/Chol
DSPC/DPPEPEG/Chol

After DOX-Loading

Molar Ratio

Size (nm)

PDI

Size (nm)

PDI

EE (%)

25/70/5

114.9 ± 10.9

0.205 ± 0.008

200.8 ± 14.6

0.522 ± 0.047

56.62 ± 2.06

25/70/5

117.9 ± 3.6

0.220 ± 0.033

189.3 ± 22.3

0.546 ± 0.055

53.18 ± 1.12

25/70/5

104.8 ± 3.5

0.176 ± 0.035

194.9 ± 7.0

0.253 ± 0.130

59.54 ± 0.59

95/5

101.8 ± 3.0

0.125 ± 0.067

136.9 ± 13.7

0.364 ± 0.085

57.74 ± 0.98

25/45/5/25

122.7 ± 8.19

0.081 ± 0.020

142.2 ± 9.5

0.113 ± 0.035

71.38 ± 0.61

25/45/5/25

116.5 ± 11.9

0.075 ± 0.030

128.1 ± 8.3

0.078 ± 0.021

89.86 ± 1.27

25/45/5/25

114.0 ± 5.6

0.074 ± 0.008

128.6 ± 14.2

0.104 ± 0.020

92.97 ± 1.10

70/5/25

119.9 ± 5.4

0.066 ± 0.037

138.4 ± 5.6

0.165 ± 0.092

60.98 ± 1.66

Size values are hydrodynamic diameters based on cumulative intensity. Data are presented as mean ± SD, N = 3.
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2.4. pH-Triggered Acquisition of Positive Charges on ICL Surface
The ζ-potentials of ICL and pH-insensitive liposomes at pH 6.0, 6.5, 7.0, and 7.4,
37 ◦ C were measured to assess the surface charge of ICL in relationship to pH. As shown in
Figure 4A, all three ICL consisting of DHI, DHMI, or DHDMI but no cholesterol showed
a significant increase of ζ-potential when pH was lowered from 7.4 to 6.0. Particularly,
the ζ-potential of ICL containing DHMI or DHDMI was elevated from below to above
zero, indicating the conversion of such ICL to assume positive surface charges in response
the pH drop. Furthermore, the higher the pKa of the imidazole-based lipid (DHDMI
Pharmaceuticals 2022, 15, x FOR PEERto
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6 of 23
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atively charged DPPE-PEG. As shown in Figure 5B, the mixture of model liposomes and
liposomes consisting of both imidazole-based lipids and cholesterol did not show any size
increase, which indicated that the incorporation of 25 mol% cholesterol hindered the interaction between ICL and the model liposomes at the acidic pHs under this investigation.
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cluster with negatively charged DPPE-PEG. As shown in Figure 5B, the mixture of model
liposomes and liposomes consisting of both imidazole-based lipids and cholesterol did
not show any size increase, which indicated that the incorporation of 25 mol% cholesterol
hindered the interaction between ICL and the model liposomes at the acidic pHs under
investigation.
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7.4. None
None of
of the
the formulations
formulations with
with
cholesterol
showed
enhanced
drug
release
at
lowered
pH,
which
indicates
thatthat
thethe
addition
cholesterol showed enhanced drug release at lowered pH, which indicates
addiof
cholesterol
prevented
any acidic
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Figure 6. Release of DOX from liposomes without cholesterol (A–D) and with 25% cholesterol (E–
Figure
of DOX
(A–D)
and±with
H)
over 6.
12 Release
h of incubation
at from
37 °C,liposomes
pH 6.0 andwithout
7.4. Datacholesterol
are presented
as mean
SD, N25%
= 3. cholesterol
(E–H) over 12 h of incubation at 37 ◦ C, pH 6.0 and 7.4. Data are presented as mean ± SD, N = 3.

2.7. Morphological Studies on ICL under TEM
Based on the aforementioned three pH-sensitivity studies, the ICL formulations consisting of DHI, DHMI, or DHDMI but no cholesterol were further characterized by TEM
(Figure 7). Such ICL formulations showed spherical vesicle structures at pH 7.4, thus confirming
the formation of liposomes. While DHI/DSPC/DPPE-PEG and 9 of 23
Pharmaceuticals
2022, 15, 306
DHMI/DSPC/DPPE-PEG formulations showed vesicles of smooth staining, those of
DHDMI/DSPC/DPPE-PEG showed bright patches of light staining at pH 7.4. Upon expo2.7. Morphological
on ICL under TEM
sure to lower pH 6.0,
all the threeStudies
ICL formulations
showed more bright patches, espeBased on the aforementioned
pH-sensitivity
studies, the
ICL formulations concially the DHDMI/DSPC/DPPE-PEG
formulation,three
which
showed vesicles
predominantly
sisting
of
DHI,
DHMI,
or
DHDMI
but
no
cholesterol
were
further
characterized
with clearly distinguishable bright and dark areas, which most probably represent sepa-by TEM
7). Such ICL formulations showed spherical vesicle structures at pH 7.4, thus confirmrated lipid phases (Figure
that are
differentially stained by uranyl acetate. DHMI/DSPC/DPPEing the formation of liposomes. While DHI/DSPC/DPPE-PEG and DHMI/DSPC/DPPEPEG and DHDMI/DSPC
/DPPE-PEG
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andthose
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vesicles at the
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of DHDMI/DSPC/DPPE-PEG
2+
lower pH 6.4. Because
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lower
pH 6.0, all the
ably bind to the phosphate
groups in lipid
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[32], patches,
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especially
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which
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surface
where
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that
phosphate groups of DPPE-PEG and thus hinder their binding with the uranyl ions.are
Atdifferentially stained by uranyl acetate. DHMI/DSPC/DPPE-PEG and DHDMI/DSPC/DPPE-PEG
pH 6.0, the DHMI/DSPC/DPPE-PEG formulation also showed some collapsed, non-vesiICL also showed larger and brighter vesicles at the lower pH 6.4. Because the positively
cle structures, which
would
explain
acidic
of bind
DOXto(Figure
6B). groups
2+ ) ofpH-enhanced
charged
uranyl
ionsits
(UO
the TEM stain release
preferably
the phosphate
2
The mixture ofinDHMI/DSPC/DPPE-PEG
and
model
liposomes
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different
lipid bilayers [32], the bright
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probably
represent
areas of ICL
surface where
protonated
lipids
clusterconsisted
with phosphate
groups
of DPPE-PEG and
morphology at pHthe7.4
and 6.0.imidazole-based
At pH 7.4, the
mixture
mainly
of smoothly
hinder
binding
with the
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ions. At
pHbright
6.0, thepatches
DHMI/DSPC/DPPE-PEG
stained vesicles; at thus
pH 6.0,
thetheir
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showed
both
vesicles
with
and subformulation
also
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some
collapsed,
non-vesicle
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which
would
explain its
stantially larger and brighter structures that appear to be aggregates of multiple ICL
and
acidic pH-enhanced release of DOX (Figure 6B).
model liposomes.

Figure 7. TEM images of DOX-loaded ICL formulations (A–F) and mixture of DHMI liposomes with
Figure 7. TEM images of DOX-loaded ICL formulations (A–F) and mixture of DHMI liposomes with
model liposomes (G,H) at pH 7.4 (A,C,E,G) and pH 6.0 (B,D,F,H).
model liposomes (G,H) at pH 7.4 (A,C,E,G) and pH 6.0 (B,D,F,H).

2.8. Differential ScanningThe
Calorimetry
of ICL
mixture of DHMI/DSPC/DPPE-PEG
and model liposomes also showed different
morphology at pH 7.4 and 6.0. At pH 7.4, the mixture consisted mainly of smoothly
In order to further
elucidate the phase behavior of ICL, DHI/DSPC/DPPE-PEG lipostained vesicles; at pH 6.0, the mixture showed both vesicles with bright patches and
somes were characterized
by differential scanning calorimetry. As the temperature was
substantially larger and brighter structures that appear to be aggregates of multiple ICL and
gradually increased
from
40 °C to 75 °C at pH 7.4, the DSC thermogram of
model
liposomes.
DHI/DSPC/DPPE-PEG liposomes (Figure 8A) showed one broad and tilted peak between
2.8. Differential
of ICL
56 °C and 65 °C, which
indicatedScanning
that theCalorimetry
liposomes
went through mainly one phase tranIn
order
to
further
elucidate
the
phase
of ICL,ofDHI/DSPC/DPPE-PEG
sition and therefore started with mainly one lipid phasebehavior
of a mixture
DHI, DSPC, and liposomes were characterized by differential scanning calorimetry. As the temperature was gradDPPE-PEG. At pH 6.0, the DSC thermogram
showed two distinct peaks, one at a similar
ually increased from 40 ◦ C to 75 ◦ C at pH 7.4, the DSC thermogram of DHI/DSPC/DPPErange between 60 °C
and
64
°C,
and
another
new
peak
at around
52 °Cpeak
(Figure
8A),56which
◦ C and 65 ◦ C,
PEG liposomes (Figure 8A) showed
one broad
and tilted
between
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indicated the formation of at least two lipid phases in the liposome membrane. The new
peak most probably represents a lipid phase that is rich in DSPC because liposomes of
which indicated that the liposomes went through mainly one phase transition and thereonly DSPC have a very similar gel-to-liquid phase transition temperature at 54 °C [33].
fore started with mainly one lipid phase of a mixture of DHI, DSPC, and DPPE-PEG. At
The DSC thermogram of the pH-insensitive control liposome DSPC/DPPE-PEG (Figure
pH 6.0, the DSC thermogram showed two distinct peaks, one at a similar range between
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one phase-transition peak around 53 °C at pH 7.4 and 6.0, indicating that the
60 ◦ C and 64 ◦ C, and another new peak at around 52 ◦ C (Figure 8A), which indicated the
control
liposomes
hadtwo
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mixing
lipids at membrane.
both pHs. The new peak most
formation of at least
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the
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probably represents a lipid phase that is rich in DSPC because
liposomes
of only
DSPC
◦ C in
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the DHI/DSPC/DPPE-PEG
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the phase
transition
peak
theThe
high-temperaa very similar gel-to-liquid
phase transition
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at 54
[33].
DSC therture
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of
56
°C
to
65
°C
indicates
strong
interactions
between
different
types ofone
lipid
mogram of the pH-insensitive control liposome DSPC/DPPE-PEG (Figure 8B) showed
◦
molecules,
most probably
DHI53and
DPPE-PEG,
than interactions
between
the same
phase-transition
peak around
C at
pH 7.4 andrather
6.0, indicating
that the control
liposomes
type
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in of
thelipids
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membrane.
hadof
homogenous
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at both
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Figure
of pH-sensitive
pH-sensitiveICL
ICL(DHI/DSPC/DPPE-PEG)
(DHI/DSPC/DPPE-PEG)(A)
(A)
and
pH-insensitive
Figure8.8.DSC
DSCthermograms
thermograms of
and
pH-insensitive
stealth
liposome
DSPC/DPPE-PEG
(B)
at
pH
7.4
and
6.0.
stealth liposome DSPC/DPPE-PEG (B) at pH 7.4 and 6.0.

2.9. Anticancer
of ICL
on 2D
Monolayer tail
Cells.
As DSPCActivity
carries the
longest
hydrophobic
(two C18 chains) among all the lipids of
the The
DHI/DSPC/DPPE-PEG
formulation,
the
phase
transition
peak
the high-temperature
anticancer activity of ICL formulations was
tested by
theindecrease
of the viability
◦ C to 65 ◦ C indicates strong interactions between different types of lipid
region
of
56
of 2D monolayer cancer cells (HeLa) at both neutral and mildly acidic pH 6.0–6.5 as seen
molecules, most probably DHI and DPPE-PEG, rather than interactions between the same
in tumor interstitium. As the culture media pH was adjusted from 7.4 to 6.0, the ICL fortype of lipid molecules in the liposome membrane.
mulations that consisted of an imidazole-based pH-sensitive lipid but no cholesterol
showed
higher Activity
anticancer
activity
9), Cells
especially at 10 μg/mL DOX concentration,
2.9. Anticancer
of ICL
on 2D(Figure
Monolayer
whereThe
all the
ICL
formulations
under
study
showed
significantly
higher anticancer
activanticancer activity of ICL formulations was tested
by the decrease
of the viability
ityof(see
* in Figurecancer
9) at pH
6.0(HeLa)
than pH
7.4 (p
< 0.05).
Among
three
formulations,
2D monolayer
cells
at both
neutral
and
mildlythe
acidic
pHICL
6.0–6.5
as seen
the
DHDMI/DSPC/DPPE-PEG
liposomes
that
contained
the
imidazole
lipid
(DHDMI)
in tumor interstitium. As the culture media pH was adjusted from 7.4 to 6.0,
the ICL of
the
highest pKathat
showed
the best
activitypH-sensitive
on the monolayer
HeLa
cells. By conformulations
consisted
of ananticancer
imidazole-based
lipid but
no cholesterol
trast,
no higher
difference
in theactivity
anticancer
activity
of the at
pH-insensitive
control
liposomes
showed
anticancer
(Figure
9), especially
10 µg/mL DOX
concentration,
(DSPC/DPPE-PEG)
was detected
between
pH 7.4 significantly
and 6.0. Ashigher
the positive
control,
free
where all the ICL formulations
under
study showed
anticancer
activity
(see
*
in
Figure
9)
at
pH
6.0
than
pH
7.4
(p
<
0.05).
Among
the
three
ICL
formulations,
DOX showed the highest anticancer activity (~50% cell viability at 10 μg/mL), but such
the DHDMI/DSPC/DPPE-PEG
activity
was the same at both pH liposomes
7.4 and pHthat
6.0.contained the imidazole lipid (DHDMI)
of the highest pKa showed the best anticancer activity on the monolayer HeLa cells. By
contrast,
no difference
activity ofSpheroids
the pH-insensitive control liposomes
2.10.
Anticancer
Activity in
of the
ICL anticancer
on 3D Multicellular
(DSPC/DPPE-PEG) was detected between pH 7.4 and 6.0. As the positive control, free
The ICL formulations were also tested against 3D multicellular spheroids (MCS) of a
DOX showed the highest anticancer activity (~50% cell viability at 10 µg/mL), but such
number
of cancer cell lines, including HeLa (cervical cancer), MDA-MB-231 (breast canactivity was the same at both pH 7.4 and pH 6.0.
cer), MDA-MB-468 (breast cancer), and A549 (lung cancer). Compared to monolayer cells,
MCS better mimic many features of solid tumors, including a cell cluster structure that
hinders drug penetration, a hypoxic microenvironment, and an acidic interstitium. Similar to prior reports [34,35], confocal imaging of MCS in our studies confirmed the presence
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of pH-gradient from 7–8 at the peripheral to 5.5–6.4 at the core (Supplementary Material,
Figure S4 and Table S2 [36]).
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0.001).
However,
activity
was not observed
in the
Figure S4 and Table S2 [36]).
DHDMI/DSPC/DPPE-PEG
formulation (IC50 = 9.51 ± 1.15 μM, p = 0.0693, Table 2). Against
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HeLa
MCS
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< 0.001 for of
DHI
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for DHDMI)
but the
was not
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(Figure
10A),
the
DHI/DSPC/DPPE-PEG
and
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ICL
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± 1.13
µM,
50 =comparable
PEG
ICL showed
the best
anticancer
activity,
which
that2.07
of the
positive
respectively,
Table
2)
than
the
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respectively, Table 2) than the pH-insensitive control liposomes (IC50 = 1.24 ± 0.13 µM;
p < 0.001 for DHI and DHMI, p < 0.01 for DHDMI) but the improvement was not as large as
on HeLa MCS. Against both HeLa and MDA-MB-468 MCS, the DHMI/DSPC/DPPE-PEG
ICL showed the best anticancer activity, which was comparable to that of the positive
control, free DOX. However, ICL did not show noticeable improvement in activity against
A549 (Figure 10B) or MDA-MB-231 (Figure 10C) MCS, compared with pH-insensitive
control liposomes. When 25 mol% cholesterol was included in the lipid composition
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all the ICL formulations showed similar but not better anticancer activity
compared with pH-insensitive liposomes against HeLa, A549, or MDA-MB-231 MCS.
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Table 2. IC50 values of DOX-loaded liposomes and free DOX on HeLa, A549, MDA-MB-231, and
MDA-MB-468 3D MCS.

Liposome Membrane
Composition
DHI/DSPC/
DPPE-PEG
DHMI/DSPC/
DPPE-PEG
DHDMI/DSPC/
DPPE-PEG
DSPC/DPPE-PEG
DHI/DSPC/DPPEPEG/Chol
DHMI/DSPC/DPPEPEG/Chol
DHDMI/DSPC/DPPEPEG/Chol
DSPC/DPPEPEG/Chol
Free DOX

IC50 $ (µM)
Lipid Molar Ratio

Hela

A549

MDAMB-231

MDAMB-468

25/70/5

3.82 ± 1.13 ***

~30 #

1.38 ± 1.31

0.38 ± 0.21 **

25/70/5

2.07 ± 1.13 ***

~40 #

1.77 ± 1.21

0.31 ± 0.15 ***

25/70/5

9.51 ± 1.15

~35 #

1.86 ± 1.24

0.63 ± 0.10 **

~35

#

2.37 ± 1.29

1.24 ± 0.13

~30

#

5.13 ± 1.46

-

95/5
25/45/5/25

11.41 ± 1.28
~10

#

25/45/5/25

10.38 ± 1.33

29.07 ± 2.73

3.62 ± 1.17

-

25/45/5/25

~10 #

24.06 ± 1.40

3.26 ± 1.18

-

70/5/25

~10 #

33.88 ± 1.62

3.98 ± 1.10

-

-

1.26 ± 0.04

12.59 ± 1.05

1.18 ± 0.29

0.32 ± 0.12

$ Calculated from dose-response data using GraphPad software. Data are presented as mean ± SD, N = 4. ** p < 0.01,
*** p < 0.001 compared to the IC50 of DSPC/DPPE-PEG. # Visual estimation from dose-response curve.

3. Discussion
Two decades of investigations on nano-drug delivery systems have established the
importance of their physicochemical properties in targeting the payload drug to cancer
cells (also known as physical targeting) [37]. Such physicochemical properties include size,
shape, surface charge, surface hydrophilicity, drug-loading, and drug release [37]. The
introduction of new characteristics such as active targeting or pH-sensitivity needs to be
accomplished in coordination with such properties, which poses a considerable challenge
to formulation development.
In this study on ICL, the three imidazole-based lipids triggered PEGylated liposomes
by efficiently clustering with phospholipid-PEG conjugates. Such a feature differentiates
them from the imidazole lipid reported by Ju et al. [24] and represents a novel approach
to construct stealth liposomes with pH-sensitivity. The clustering action is most probably
achieved by the three lipids’ unique structure, in which the imidazole headgroup is linked
to the lipid tail at the C2 position through a carbon-sulfur bond so that both nitrogen
atoms of the imidazole group can serve as H-bond donors upon protonation at acidic pH
(Figure 2). The protonated imidazole groups can then each bind with negatively charged
phosphate groups from two different DPPE-PEG molecules, which in turn crosslink DPPEPEG molecules into clusters on the ICL surface. As PEGylation serves as a key method to
construct long-circulating liposomes for anticancer drug delivery by the EPR effect, the
imidazole-based lipids under this study have the potential for wide applications in vivo.
Compared to the doxorubicin-loaded PEG liposomes (Doxil® ) that are in current clinical use, ICL carries the advantage of pH-sensitivity while preserving the physicochemical
properties that favor passive targeting to solid tumors. The drug-free ICL carried sizes
under 130 nm in diameter while the DOX-loaded ICL formulations carried sizes under
or around 200 nm, both of which were within the size range for the EPR effect [9]. The
increase of size and PDI of ICL upon DOX-loading was probably due to the aggregation of
DOX molecules with the liposomes because our attempts to load higher concentrations of
DOX led to precipitation and because DOX had been reported to aggregate with negatively
charged liposomes [38]. DOX can be loaded into ICL at >50% encapsulation efficiency (EE)
and at sufficiently high concentrations (Table 1) for anticancer studies in cell culture [39].
The payload DOX concentration of ICL could be further elevated by concentrating DOX-
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loaded ICL using Tangential Flow Filtration [40]. Although DOX is elected as the cargo
drug in this study for better comparison between ICL and clinically established liposomal
formulations, we anticipate that the imidazole lipids under this study can be used to trigger
PEGylated liposomes containing various water-soluble anticancer drugs.
In response to the drop of pH, ICL without cholesterol demonstrated a number of
substantial changes in their physicochemical properties, including acquisition of positive
surface charges (ζ-potential elevation in Figure 4A), lipid phase separation (DSC studies
in Figure 8A and TEM images in Figure 7), binding with the bio-mimetic membrane
(aggregation with model liposomes in Figure 5A), and enhanced release of the payload
drug DOX (Figure 6). The extent of most of the changes, namely the positive surface charge
acquisition, lipid phase separation, and binding with bio-mimetic membrane, are correlated
with higher basicity of the imidazole lipid (DHDMI > DHMI >DHI). This correlation can
be explained by our proposed mechanism of ICL’s pH-sensitivity, where the more basic
imidazole lipid would be protonated more at the same mildly acidic pH, which would
yield more positive charges on liposome surface and more electrostatic interaction between
the imidazole lipid and DPPE-PEG, which would, in turn, promote phase separation of
ICL membranes and binding between ICL and bio-mimetic membranes. Interestingly,
DOX release from ICL did not follow such correlation in that only ICL consisting of
DHMI showed substantially enhanced DOX release when the pH dropped from 7.4 to
6.0. TEM images of DHMI/DSPC/DPPE-PEG in comparison to DHI/DSPC/DPPE-PEG
and DHDMI/DSPC/DPPE-PEG suggest that this pH-triggered release may be caused
by DHMI/DSPC/DPPE-PEG’s unique tendency to collapse into non-lamellar structures
at pH 6.0. Alternatively, DHMI/DSPC/DPPE-PEG’s membrane might also have more
structural defects at the edge between the separated lipid phases at pH 6.0 to enhance the
DOX release.
The incorporation of 25 mol% cholesterol prevented the size increase of ICL during
DOX-loading; it also elevated the EE and the payload DOX concentration in ICL. This
was probably because cholesterol can improve the stability of the lipid bilayer structure
in the ICL formulations. During drug-loading, when the temperature is above the lipid
bilayer transition temperature (T > Tm ), the liposome membrane was in the fluid phase,
in which the lipid molecules were free to move laterally. The addition of cholesterol was
found to help suppress the mobility of lipid bilayers in the fluid phase and reduce their
permeability to water, thus improving the membrane stability and drug retention during
drug loading [41]. The introduction of cholesterol also diminished the pH-sensitivity
of ICL (Figures 4–7), probably because the incorporation of cholesterol obstructed the
lateral movements of lipids in bilayers at T < Tm . The nonpolar cholesterol molecules
were found to tie up the neighboring lipid’s hydrocarbon chains to minimize cholesterol
molecules’ thermodynamically unfavorable exposure to water at the membrane-water
interface [42]. In ICL, such cholesterol-lipid interaction would substantially limit the
movement of the imidazole-based lipids and DPPE-PEG, thus hindering their clustering at
acidic pH. Furthermore, ICL with cholesterol maintained negative ζ-potentials at acidic
pH, indicating that the protonation of the imidazole-based lipids was also suppressed
by cholesterol (Figure 4B). This is probably because the addition of cholesterol increases
the hydrophobicity of the liposome membrane, which in turn reduces its affinity with
cations [43].
The targeting of cytotoxic chemotherapy drugs to enhance their efficacy and safety
is a complicated process with multiple challenges that all need to be addressed by the
drug delivery system, including preferred distribution of the drug molecules from blood
circulation to the tumor interstitium, sufficient permeation of the drug molecules to all
areas of the solid tumor, and uptake of the drug molecules by virtually all the cancer cells
in the tumor. It is therefore critical that anticancer drug delivery systems are evaluated by
biological models that simulate these multiple challenges. ICL formulations under this
study were evaluated by both monolayer cancer cells and 3D MCS in culture in order to
test the potential of their pH-sensitivity to enhance the anticancer activity [34].
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In monolayer Hela cells, ICL’s higher ability to suppress cell viability is strongly
correlated with lower pH and higher pKa, which are both correlated with the acquisition
of positive charges on the ICL surface, ICL’s phase separation, and ICL’s interaction with
negatively charged bio-mimetic membranes. Such strong correlations suggest that ICL’s
activities to suppress monolayer cell viabilities can be attributed to ICL’s enhanced binding
to the cancer cells at lowered pH. More specifically, the drop of pH protonates the imidazole
lipids, which cluster DPPE-PEG lipids to expose a de-PEGylated and positively charged
ICL surface, which in turn binds to the cancer cell surface to induce the endocytosis of the
DOX-loaded ICL and consequently the cell death.
The ICL’s pattern of suppressing the cell viability in 3D multicellular spheroids was
quite different from that in 2D monolayer cells. Overall, ICL consisting of DHMI, the
imidazole lipid of the second-highest calculated pKa (6.20 ± 0.5), yielded the highest
activity to suppress MCS viability, rather than DHDMI of the highest calculated pKa
(6.75 ± 0.5). This is probably due to the dynamic balance between the binding of ICL to the
cancer cells in MCS and the penetration of ICL to reach the most cancer cells in MCS. On
the one hand, DHI may carry too low a pKa (5.53 ± 0.5) to sufficiently trigger its ICL in the
mildly acidic microenvironment of MCS; on the other hand, DHDMI may carry too high a
pKa, which would trigger most of its ICL to bind to only the cancer cells in the peripheral
region of MCS. Paradoxically, DHMI may carry the optimal basicity (pKa 6.20 ± 0.5, closest
to the measured interstitial pH of MCS) to facilitate both the penetration and the cellular
binding of its ICL. Furthermore, among all the ICL under this study, DHMI/DSPC/DPPEPEG showed the unique property of pH-enhanced drug release, which would allow such
ICL to selectively release DOX in the MCS interstitium to kill multiple adjacent cancer cells,
also known as the bystander effect [44].
4. Materials and Methods
4.1. Materials
1,2-Di-O-hexadecyl-rac-glycerol (DHG), 2-mercaptoimidazole, 4-methyl-1H-imidazole2-thiol, and 4,5-dimethyl-1H-imidazole-2-thiol were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). p-Toluenesulfonyl chloride, 2-[4-(2-hydroxyethyl)piperazin-1yl]-ethanesulfonic acid (HEPES), and 2-(N-morpholino)ethanesulfonic acid (MES) were
purchased from Fisher Scientific (Hampton, NH, USA). Triethylamine (TEA) was purchased from Alfa Aesar (Haverhill, MA, USA). The lipids 1,2-distearoyl-sn-glycero-3phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[azido(poly
-ethylene glycol)-2000 (DPPE-PEG (2000)), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1-palmitoyl-2oleoyl-sn-glycero-3-phospho-L-serine (sodium salt) (POPS) and L-α-phosphatidylinositol
(Soy) (L-R-PI) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Cholesterol, Dowex® 50WX-4 (50–100 mesh), Sephadex G-25, and Uranyl acetate (UA) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Doxorubicin hydrochloride was
purchased from Biotang (Waltham, MA, USA). Carbon-coated copper grids (200 mesh) for
electron microscopy were purchased from Polysciences (Warrington, PA, USA). The HeLa,
A549, MDA-MB-231 and MDA-MB-468 cell lines were purchased from ATCC (Manassas,
VA, USA). The Dulbecco’s Modified Eagle’s Medium (DMEM), Advanced DMEM/F12
medium, Trypsin-EDTA, L-glutamine, fetal bovine serum, and collagen were purchased
from Thermo-Fisher Scientific (Waltham, MA, USA). The RPMI 1640 medium, penicillinstreptomycin, 96-well Ultra-low Attachment round-button microplates, 96-well solid white
microplates, CellTiter-Glo 3D cell viability assay kits and MTS CellTiter 96® AQueous One
Solution cell proliferation assay kits (Promega Corp., WI, USA) were purchased from VWR
(Radnor, PA, USA). All other organic solvents and chemicals were purchased from SigmaAldrich (St. Louis, MO, USA), Fisher Scientific (Hampton, NH, USA) or VWR (Radnor,
PA, USA).
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4.2. Synthesis of 2,3-di-O-Hexadecyl-1-rac-glyceryl-tosylate (DHG-Tosylate)
1,2-Di-O-hexadecyl-rac-glycerol (DHG) (2.30 g, 4.25 mmol) was mixed with anhydrous dichloromethane (20 mL) and pyridine (18.6 mL, 225 mmol). p-Toluenesulfonyl
chloride (1.90 g, 9.97 mmol) was dissolved in ~0.5 mL anhydrous dichloromethane and
transferred into the mixture. The reaction mixture was stirred under argon at room temperature for 8 to 12 h. The reaction mixture was then mixed well with 10 mL anhydrous
dichloromethane and washed with saturated Na2 CO2 solution 3 times. The organic phase
was separated from the aqueous phase, dried with MgSO4 , filtered, and then evaporated
into dryness under vacuum. The resultant residue was separated by silica gel chromatography with dichloromethane as the mobile phase to yield 2.53 g solid (86%). DART
Mass Spectrum: 695.5; calculated, 695.6 (MH)+ . 1H-NMR (600 MHz, CDCl3 , δ ppm):
0.87 (t, 6H, 2 CH3 (CH2 )15 -), 1.18–1.31 (m, 52H, 2 OCH2 CH2 (CH2 )13 CH3 ), 1.46 (m, 4H, 2
OCH2 CH2 (CH2 )13 CH3 ), 2.44 (s, 3H, -(C6 H4 )CH3 ), 3.31–3.62 (m, 7H, glyceryl/hexadecyl
-CH2 O and -CHO-), δ 4.14 (m, 2H, -CH2 OSO2 -), δ 7.33 (d, 2H, aromatic protons ortho to
-CH3 ), and δ 7.78 (d, 2H, aromatic protons ortho to -SO2 -).
4.3. Synthesis of sn-2-((2,3-Dihexadecyloxypropyl)thio)-1H-imidazole (DHI)
2-Mercaptoimidazole (0.91 g, 9.06 mmol) was dissolved in 8–9 mL of anhydrous
N, N-dimethylformamide (DMF). DHG-tosylate (1.265 g, 1.82 mmol) was dissolved in
7–8 mL of anhydrous dichloromethane and transferred into the above-mentioned solution,
followed by the addition of triethylamine (TEA, 1.27 mL, 9.08 mmol). The reaction mixture
was stirred under argon at 55 ◦ C for 48 h. The solvent was evaporated under a vacuum,
and the resultant residue was dissolved in dichloromethane. The solution was washed
with saturated sodium bicarbonate solution 3 times, dried with sodium carbonate, filtered,
and then evaporated into dryness under vacuum. The resultant residue was then separated
by silica gel chromatography with 1–5 vol% methanol in dichloromethane as the mobile
gradient phase to yield DHI (25–30%). DART Mass Spectrum: 623.48 (Figure S1); calculated,
623.55 (MH)+ . 1H-NMR (Figure S2, 600 MHz, CDCl3 ): δ 0.87 (t, 6H, 2 CH3 (CH2 )15 ), δ 1.19–1.32 (m, 54H, 2 -OCH2 CH2 (CH2 )13 CH3 and -H2 CSCNH-), δ 1.55 (m, 4H, 2
OCH2 CH2 (CH2 )13 CH3 , δ 3.2–3.7 (m, 7H, glyceryl/hexadecyl -CH2 O and -CHO-), δ 7.02 (d,
1H, H2 CSC-NHCH=CH-N=), δ 7.21 (d, 1H, H2 CSC-NHCH=CH-N=). Elemental analysis:
C 73.27%, H 12.25%, N 4.56%; calculated: C 73.25%, H 11.97%, N 4.50%. Calculated pKa
using ACD/pKa DB software: 5.53 ± 0.5.
4.4. Synthesis of sn-2-((2,3-Dihexadecyloxypropyl)thio)-5-methyl-1H-imidazole (DHMI)
4-Methyl-1H-imidazole-2-thiol (1.03 g, 9.03 mmol) was used to prepare DHMI, using the same synthesis method as DHI. Yield: 25–30%. DART Mass Spectrum: 637.55
(Figure S1); calculated, 637.57 (MH)+ . 1H-NMR (Figure S2, 600 MHz, CDCl3 ): δ 0.87 (t, 6H,
2 CH3 (CH2 )15 -), δ 1.19–1.34 (m, 54H, 2 -OCH2 CH2 (CH2 )13 CH3 and -H2 CSCNH-), δ 1.53
(m, 4H, 2 OCH2 CH2 (CH2 )13 CH3 ), δ 2.41 (s, 3H, -H2 CSC-NH-C(CH3 )-), δ 3.2–3.7 (m, 7H,
glyceryl/hexadecyl -CH2 O and -CHO-), δ 6.81 (s, 1H, -H2 CSC=N-CH=). Elemental analysis:
C 73.63%, H 12.08%, N 4.35%; calculated: C 73.52%, H 12.02%, N 4.40%. Calculated pKa
using ACD/pKa DB software: 6.20 ± 0.5.
4.5. Synthesis of sn-2-((2,3-Dihexadecyloxypropyl)thio)-4,5-dimethyl-1H-imidazole (DHDMI)
4,5-Dimethyl-1H-imidazole-2-thiol (1.15 g, 9.03 mmol) was used to prepare DHDMI,
using the same synthesis method as DHI. Yield: 25–30%. DART Mass Spectrum: 651.56
(Figure S1); calculated, 651.59 (MH)+ . 1H-NMR (Figure S2, 600 MHz, CDCl3 ): δ 0.87 (t, 6H,
2 CH3 (CH2 )15 –), δ 1.19–1.34 (m, 54H, 2 -OCH2 CH2 (CH2 )13 CH3 and -H2 CSCNH-), δ 1.53 (m,
4H, 2 OCH2 CH2 (CH2 )13 CH3 ), δ2.22 (s, 3H, -H2 CSC-NHC(CH3 )=), δ2.24 (s, 3H, -H2 CSC=NC(CH3 )=), δ 3.3–3.7 (m, 7H, glyceryl/hexadecyl -CH2 O and -CHO-). Elemental analysis:
C 73.78%, H 12.24%, N 4.16%; calculated: C 73.78%, H 12.07%, N 4.30%. Calculated pKa
using ACD/pKa DB software: 6.72 ± 0.5.
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4.6. Preparation of ICL Formulations
A dichloromethane solution of an imidazole-based lipid and a chloroform solution of
other lipids were mixed in a round-bottom flask. The organic solvents were evaporated
under reduced pressure to form a lipidic film at 70 ◦ C. The lipidic film was further dried in
a high vacuum for over 4 h at room temperature to remove the residual solvent. The lipidic
film was then hydrated with HEPES buffer (pH 7.4, 30 mM HEPES) containing 300 mM
MnSO4 by intermittent agitation in a 70 ◦ C water bath under argon to obtain a liposome
suspension containing 20 mM total lipids. The liposome suspension was freeze-annealthawed by rapidly freezing in liquid nitrogen, immerging in the ice-water mixture for 2 min
and incubating in a 70 ◦ C water bath for 4 min. The freeze-anneal-thawing was repeated
11 times. The liposome suspension was sequentially extruded 21 times each through 400 nm,
200 nm and 100 nm polycarbonate membranes (Nucleopore Corp., Pleasanton, CA, USA)
using a hand-held Mini-extruder (Avanti Polar Lipids Inc., Alabaster, AL, USA) at 70 ◦ C to
reduce and homogenize the size of liposomes. DOX was then loaded into the liposomes
as follows, using a transmembrane MnSO4 gradient [45]. The extruded liposomes were
separated from the unencapsulated MnSO4 by size exclusion chromatography using a
Sephadex G-75 column pre-equilibrated with isotonic HEPES buffer (pH 7.4, 5 mM HEPES,
140 mM NaCl). DOX (0.75 mg/mL) dissolved in the same isotonic HEPES buffer was then
mixed with the liposome suspension in a 1:2 (v/v) ratio, and the mixture was incubated in
a 70 ◦ C water bath for 90 min. The cation-exchange resin Dowex® 50WX-4, 50–100 mesh
was pre-treated with NaOH and NaCl [46], mixed with the DOX-liposome mixture at DOX:
resin = 1:60 (w/w), and then shaken gently for 25 min to remove the unencapsulated DOX
from the DOX-loaded liposomes. The resin was separated from the DOX-loaded liposomes
by filtration. A tangential flow filtration column (MicroKros® , Spectrum, Stamford, CT,
USA) was used to concentrate the liposome suspension by partially removing the extraliposomal buffer. Typically, a 2 mL liposome suspension was extruded 14 times through
the tangential flow filtration column to yield a ~0.5 mL concentrated formulation. The lipid
composition of the liposomes under study is listed in Table 3.
Table 3. Lipid composition of liposomes under study.
Mol %
Formulations
I
II
III
IV
V
VI
VII
VIII

DHI

DHMI

DHDMI

DSPC

DPPE-PEG

Chol

25
25
-

25
25
-

-

70
70
70
95
45
45
45
70

5
5
5
5
5
5
5
5

25
25
25
25

25
25
-

I–III and V–VII are ICL; IV and VIII are PEGylated, pH-insensitive liposomes as controls; V–VIII contain cholesterol,
and I–IV does not contain cholesterol.

4.7. Size Measurement
An aliquot (2.5–5 µL) of a liposome suspension was diluted in 150 µL isotonic buffer,
and the size was measured at room temperature by dynamic light scattering (Zetasizer
ZS90, Malvern Instruments Ltd., Malvern, UK). The data were analyzed based on light
intensity distribution to give hydrodynamic diameters.
4.8. Quantification of Encapsulation Efficiency (EE)
An aliquot (10 µL) of DOX-loaded liposome suspension was lysed with 90 µL lysis buffer (90% (v/v) isopropanol, 0.075 M HCl) [46] in a 96-well Black Clear Bottom
Polystyrene microplate (Corning® , NY, USA), together with 10 µL DOX standard solutions
diluted in the same lysing buffer (90 µL). The microplate was covered with foil, and the
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fluorescence of the samples (λex = 486 nm, λem = 590 nm) was recorded on a Synergy HT
microplate reader (Biotek, Winooski, VT, USA). The concentration of the payload DOX
of liposomes was estimated using a standard calibration curve from the fluorescence of
the DOX standard solutions. The encapsulation efficiency (EE) of the liposomes was then
calculated by the following formula.
EE =

Encapsulated DOX Conc.
× 100%
Input DOX Conc. for drug loading

4.9. Differential Scanning Calorimetry
A VP-DSC Instrument (MicroCal, LLC, Northampton, MA, USA) was used for the
differential scanning calorimetry (DSC) studies. DSC scans were performed on 0.5 mL
liposome suspensions containing 2.5 mM total lipids at pH 7.4 and pH 6.0. The thermograms of liposome suspensions were acquired from 40 ◦ C to 75 ◦ C at a scan rate of 5 ◦ C/h.
Each excess heat capacity curve of a liposome sample was normalized by subtraction of the
thermogram of the buffer acquired simultaneously under identical conditions.
4.10. pH-Triggered Change of ζ-Potential
In order to enhance the detection of changes in liposome surface charge, the liposomes
were prepared by hydration in an isotonic buffer of low ionic strength (pH 7.4, 5 mM
HEPES, 5% (w/v) Glucose) [47]. Aliquots (50–100 µL) of the resultant liposome suspensions
were diluted in 900 µL isotonic MES buffer (final pH 6.0 and 6.5, 10 mM MES, 5% (w/v)
Glucose) and 900 µL isotonic HEPES buffer (final pH 7.0 and 7.4, 10 mM HEPES, 5% (w/v)
Glucose). The ζ-potential was then measured at 37 ◦ C based on electrophoresis mobility
under applied voltage (Zetasizer ZS90, Malvern Instruments Ltd., Malvern, UK).
4.11. pH-Dependent Interaction with Model Liposomes
The model liposomes (POPC:POPE:POPS:L-R-PI:cholesterol = 50:20:5:10:15 (mol%))
mimicking the lipid composition and surface charge of biomembranes were prepared
based on a previous report [31]. As measured by Zetasizer ZS90, the mean size of the
model liposomes was 192.7 nm in diameter, and the ζ-potential was −51.77 ± 1.18 mV.
Suspensions of ICL and pH-insensitive control liposomes were each mixed with the model
liposomes at a 1:1 total lipid molar ratio. An aliquot (5 µL) of each mixture was diluted in
150 µL isotonic MES buffer (final pH 6.0 and 6.5, 10 mM MES, 140 mM NaCl) and isotonic
HEPES buffer (final pH 7.0 and 7.4, 10 mM HEPES, 140 mM NaCl), and incubated at 37 ◦ C
for 5 min. The particle size of the diluted mixtures was measured at 37 ◦ C by dynamic light
scattering (Zetasizer ZS90, Malvern Instruments Ltd., Malvern, UK).
4.12. pH-Dependent Drug Release
Each liposome formulation was severally diluted (100 µL aliquots) with 500 µL MES
buffer (final pH 6.0 and 6.5, 100 mM MES, 1.7% (w/v) Glucose) and HEPES buffer (final
pH 7.0 and 7.4, 100 mM HEPES, 1.7% (w/v) Glucose). An aliquot (10 µL) of each diluted
liposome formulation was immediately lysed with 90 µL lysis buffer (90% (v/v) isopropanol,
0.075 M HCl) in a 96-well Black Clear Bottom Polystyrene microplate and the initial DOX
concentration Ci (as at the 0-h time point) was qualified with standard DOX solutions. The
liposome samples diluted by buffers at various pH (6.0, 6.5, 7.0, 7.4) were then mixed with
cation-exchange resin Dowex® 50WX-4 (50–100 mesh) at DOX:resin = 1:200 (w/w) ratio.
The mixtures were incubated and gently shaken at 37 ◦ C. At different time points (1, 3, 6,
12 h), each mixture was allowed to settle briefly, and an aliquot (10 µL) of the resultant
supernatant was harvested, lysed, and its DOX concentration measured as mentioned
before. The percentage of DOX release was determined by the following equation,


Cs
% Release = 1 −
× 100%
Ci
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where Cs is the concentration of DOX in the supernatant of the liposome-resin mixture at
different time points, Ci is the initial liposomal DOX concentration.
4.13. Transmission Electron Microscopy
The morphology of ICL formulations was observed on a JEOL-JEM 1230 Electron
Microscope (JEOL, Tokyo, Japan). Carbon-coated copper TEM grids (200 mesh) were
subjected to glow discharge before usage to increase their hydrophilicity. An aliquot (5 µL)
of diluted ICL suspension (approximately 1 mM total lipids) at pH 7.4 or 6.0 was dripped
onto the grid to wet its surface for 1 min and then blotted with filter paper to generate a thin
film. The sample film was then wetted five times with 5 µL of the negative stain 2% uranyl
acetate (UA) between blotting. The grid was dried at room temperature and then transferred
into the electron microscope for imaging at an accelerating voltage of 100 kV. The samples
of ICL mixed with model liposomes were prepared and imaged by the same method.
4.14. Cell Culture
Cervical cancer cell line HeLa, lung cancer cell line A549, and breast cancer cell lines
MDA-MB-231 and MDA-MB-468 were cultured to construct 3D MCS in order to evaluate
the anticancer activities of ICL. Hela cells were also cultured into monolayer cells. HeLa
cells were maintained in DMEM media; A549 cells were maintained in RPMI 1640 media;
MDA-MB-231 and MDA-MB-468 cells were maintained in advanced DMEM/F12 media.
All media were supplemented with 10% fetal bovine serum, 1% Penicillin-Streptomycin,
and 1% L-glutamine. All cells were grown in a humidified atmosphere of 5% CO2 in air
at 37 ◦ C and passaged at 85% confluence. In all studies, the cells were sub-cultured every
2–3 days and used for experiments at passages 5–20.
4.15. Cytotoxicity Assays on 2D Monolayer Hela Cells
Monolayer HeLa cells at ~85% confluence were suspended by trypsinization, and
the cell density was determined with a Handheld Automated Cell Counter (Millipore,
Burlington, MA, USA). The cells were then diluted to ~80,000 cells/mL in complete growth
media and seeded into 96-well Clear Microplates (Corning, NY, USA) at ~8000 cells/well
by transferring 100 µL of the cell suspension into each well. The cytotoxicity assay was
carried out on the cells 8 h after they were seeded. The cells were washed with PBS and
treated with DOX-loaded liposomes or free DOX solutions in complete growth media at
incremental concentrations. The pH of the media (10 mL) was adjusted to 7.4, 7.0, 6.5,
and 6.0 with glacial acetic acid. After 12-h incubation, the media was removed, and the
cells were washed with 100 µL PBS buffer and supplemented with 100 µL/well complete
growth media and 20 µL/well MTS CellTiter 96® AQueous One Solution. The mixture was
incubated for 4 h at 37 ◦ C with 5% CO2 . The cell viability was quantified by UV/visible
absorbance at 490 nm on a Synergy HT microplate reader (Biotek, Winooski, VT, USA).
The Hela cells treated with growth media at corresponding pHs without free DOX or
DOX-loaded liposomes were referred to as 100% cell viability.
4.16. Cytotoxicity Assays on 3D Multicellular Spheroids
Monolayer cells in T75 flasks were trypsinized, and the cell density in the suspensions was
determined with a Handheld Automated Cell Counter. The cells were then seeded into 96-well
Ultra-low Attachment (ULA) round-bottom microplates (Corning, NY, USA) at ~500 Hela
cells/well, ~5000 A549 cells/well, ~3000 MDA-MB-231 cells/well, and ~2000 MDA-MB468 cells/well by transferring 100 µL properly diluted cell suspensions in complete growth
media containing collagen (0% for HeLa, 0.3% for A549, 1% for MDA-MB-231, and 1% for
MDA-MB-468 cell lines). If needed, the microplates were centrifuged at 7 ◦ C to promote
cell aggregation (Table S1). Complete growth media (100 µL) was added to each well on
the second day after seeding. The growth media were then partially exchanged every
other day by replacing 100 µL of media in each well with 100 µL fresh media to maintain a
200 µL/well total media volume. The cytotoxicity assays were carried out on selected MCS
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whose diameter reached or exceeded 500 µm (Figure S3) [48,49]. Part of the growth media
(100 µL/well) was replaced with the same volume of DOX-loaded liposomes or free DOX
solutions in complete growth media at incremental concentrations. After 72 h incubation,
each MCS was transferred into a well of a 96-well Solid White microplate (Corning, NY,
USA) together with 100 µL media. Then, 100 µL reagent of the CellTiter-Glo 3D cell viability
assay was then added to each well, and the microplate was covered with foil, shaken on an
orbital shaker for 5 min, and then incubated for 25 min at room temperature. The viability
of MCS was then measured by luminescence intensity on a Synergy HT microplate reader
(Biotek, Winooski, VT, USA). The MCS treated by growth media without free DOX or
DOX-loaded liposomes was referred to as 100% cell viability.
5. Conclusions
Novel imidazole-based convertible liposomes (ICL) have been designed and constructed. ICL carries a PEG-coating and slight excess of negative surface charges at pH 7.4.
As pH decreased to 6.0, the imidazole-based lipids assumed positive charges and clustered
with negatively charged PE-PEG conjugates in ICL, which in turn partially de-PEGylated
the liposomes to enhance their adsorption to negatively charged, bio-mimetic membranes.
The drop of pH to 6.0 also enhanced the release of the anticancer drug DOX from ICL that
consisted of the imidazole lipid DHMI (>50% release in 6 h), but not those of the other two
imidazole-based lipids. TEM studies suggest that DHMI enhanced the drug release from
ICL due to its ability to convert the liposomal membrane into non-lamellar structures. The
incorporation of cholesterol improved the colloidal stability of ICL but diminished their pHsensitivity. ICL demonstrated substantially higher anticancer activities than the analogous
PEGylated, pH-insensitive liposomes containing doxorubicin, which is a common type of
nano-formulations in clinical use. While the anticancer activities of ICL against monolayer
Hela cells are correlated with higher pKa of the imidazole lipid, the anticancer activities
against 3D multicellular spheroids are the highest in ICL that consisted of the imidazole
lipid DHMI, which possesses the medium pKa and enhances the liposomal drug release at
pH 6.0. Our studies on ICL suggest that nano-drug delivery systems that balance the needs
of intratumoral penetration, adsorption to cancer cells, and enhanced drug release would
yield optimal anticancer activities.
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imidazole-based lipids DHI (A), DHMI (B), and DHDMI (C); Figure S3: Representative morphology
of MCS with a diameter of ~500 µm in the ULA 96-well microplates for anticancer drug treatment;
Figure S4: Representative confocal images of 3D MCS for intra-MCS pH measurements; Table S1:
Conditions to culture 3D MCS of cancer cells; Table S2: Calculated pH in 3D MCS of Hela, A549, and
MDA-MB-468 cancer cells based on fluorescent images of confocal microscopy.
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